Leerink Partners Downgrades Alpine Immune Sciences to Market Perform, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Thomas Smith downgraded Alpine Immune Sciences (ALPN) from Outperform to Market Perform while raising the price target from $42 to $65.
April 12, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alpine Immune Sciences was downgraded by Leerink Partners from Outperform to Market Perform, though its price target was increased from $42 to $65.
The downgrade to Market Perform suggests a neutral outlook on ALPN's stock performance in the short term, indicating that the stock might not outperform the market as previously expected. However, the increase in the price target from $42 to $65 reflects a positive adjustment in the valuation of the company, suggesting that the stock has potential for growth. The mixed nature of this update (a downgrade in rating but an increase in price target) could lead to varied interpretations by investors, potentially resulting in neutral short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100